IBio's IBIO-610 Achieves Near-Complete Activin E Inhibition In Obese Primate Study

India, July 1 -- iBio, Inc. (IBIO) announced new preclinical results showing that a single dose of its antibody candidate IBIO-610 reduced active Activin E levels by up to 98% in obese non-human primates, with suppression lasting through eight weeks.

The study demonstrated that IBIO-610 not only achieved durable pathway inhibition but also promoted fat-selective weight loss. When combined with Semaglutide, the therapy drove greater visceral and total fat reduction while cutting lean mass loss by 73% compared with Semaglutide alone.

Martin Brenner, DVM, Ph.D., iBio's CEO and CSO, said the findings represent the highest degree of Activin E inhibition reported to date in this class, achieved with a single dose. He noted the potential for low...